Multiple clinical trials have reported that AMPK agonist metformin combined with EGFR-TKIs can prolong the progression-free survival (RFS) in EGFR-mutated NSCLC compared to EGFR-TKIs alone [61,62]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.